Tiziana Life Sciences shares rise 12.59% premarket as CEO to present Intranasal Foralumab at Neuroscience Innovation Forum during J.P. Morgan Healthcare Conference Week.
ByAinvest
Monday, Jan 12, 2026 4:39 am ET1min read
TLSA--
Tiziana Life Sciences surged 12.59% in premarket trading following news that its CEO will present Intranasal Foralumab at the Neuroscience Innovation Forum during the J.P. Morgan Healthcare Conference Week on January 11, 2026. The announcement highlights the company’s focus on advancing its pipeline for neurological conditions, with the conference—a key industry event—likely to draw investor attention and signal progress in drug development. The timing aligns with heightened market interest in biotech innovations, reinforcing positive momentum ahead of the presentation.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet